Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

88.64 +0.74 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,364,074
Open 87.72
Bid (Size) 86.24 (20)
Ask (Size) 90.79 (1)
Prev. Close 87.90
Today's Range 87.20 - 89.03
52wk Range 73.67 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven... 
Via Benzinga

Performance

YTD
-9.60%
-9.60%
1 Month
+4.26%
+4.26%
3 Month
+10.11%
+10.11%
6 Month
+0.52%
+0.52%
1 Year
-1.83%
-1.83%

More News

Read More
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Via Benzinga
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
Via Investor's Business Daily
NASDAQ:BMRN is not too expensive for the growth it is showing.
Via Chartmill
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
Via Benzinga
Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.